Entyvio 300 MG vials
Ended Awarded
- Contract number
- SPE2DB25FSY90
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $49,449
Award facts
- Contract value 100% obligated
- $49,449.30 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $49,449.30 by the Defense Logistics Agency on July 18, 2025, for the supply of Entyvio 300 mg vials. The delivery order carries an ultimate completion date of August 8, 2025, and represents a component of DMS Pharmaceutical Group's broader engagement with the federal government through a significant Indefinite Delivery Contract with the DLA valued at $500 million through November 2026. This delivery order was not issued under any set-aside designation, and the place of performance is listed as Park Ridge, Illinois.
Entyvio is a biologic medication used to treat inflammatory bowel diseases, reflecting DMS Pharmaceutical Group's established role as a critical supplier of specialty pharmaceuticals and biologics to Department of Defense healthcare facilities nationwide. The company's federal contract portfolio demonstrates consistent success in securing pharmaceutical supply awards across a broad range of prescription medications, over-the-counter products, and specialty medical supplies that support military health system operations globally. This delivery order exemplifies the company's operational capacity to fulfill urgent pharmaceutical requirements within compressed timelines while maintaining quality standards essential to federal healthcare delivery.
Quick answers
Who was awarded contract SPE2DB25FSY90?
SPE2DB25FSY90 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on July 18, 2025.
How much is contract SPE2DB25FSY90 worth?
The government has obligated $49,449 on SPE2DB25FSY90.
Is contract SPE2DB25FSY90 an order under another contract?
Yes. SPE2DB25FSY90 is a delivery order under SPE2DB22D9367, an indefinite delivery contract.
Was contract SPE2DB25FSY90 competed?
The extent of competition for SPE2DB25FSY90 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award